Market/Novel Tech

ProQR Therapeutics N.V. (NASDAQ: PRQR), expects to enrol 36 patients of LCA10  using a novel therapy for “Sepofarsen” (QR-110)

A Dutch biotechnology company, ProQR Therapeutcis N.V., (NASDAQ:PRQR), Leiden, has announced the enrolment of a phase 2/3 study for the treatment of Leber Congenital Amaurosis… Read More »ProQR Therapeutics N.V. (NASDAQ: PRQR), expects to enrol 36 patients of LCA10  using a novel therapy for “Sepofarsen” (QR-110)

Applied Genetic Technologies Corporation (NASDAQ: AGTC; Florida, USA) has reported positive data from a Phase 1/2 study for X-linked retinitis pigmentosa.

Applied Genetic Technologies Corporation Inc. (Nasdaq: AGTC) has reported positive data from a Phase 1/2 clinical study for 28 X-linked retinitis pigmentosa (XLRP) patients.  The company… Read More »Applied Genetic Technologies Corporation (NASDAQ: AGTC; Florida, USA) has reported positive data from a Phase 1/2 study for X-linked retinitis pigmentosa.

GenSight Biologics has reported a natural history for LHON (with ND4 mutations) showing that a novel treatment could provide a convincing benefit. 

GenSight Biologics Inc., (EURONEXT: SIGHT), Paris, France, has announced the results from the final analysis of the REALITY natural history study, which reaffirms the poor… Read More »GenSight Biologics has reported a natural history for LHON (with ND4 mutations) showing that a novel treatment could provide a convincing benefit.